耐药和复发的何杰金氏病化疗中剂量强度与疗效关系的分析

The analysis of dose-response relationship in the chemotherapy of refractory and relapsed Hodgkin's disease

耐药和复发的何杰金氏病（HD）是否该作自体骨髓移值（ABMT）仍是颇有争议的问题。剂量强度与疗效的关系是ABMT的理论基础。本文研究了1982～1994年间有关HD挽救化疗资料中的剂量强度与疗效关系，没有得出所希望的结论。但常规化疗的结果并不满意，Ⅲ线方案的CR率仅23％。ABMT在Ⅱ线方案失败的患者中有很强适应症。

The role of autologous bone marrow transplantation(ABMT) in the treatment of Hodgkin's disease (HD) remains controversial. Dose-response relationship is the theoretical basis of ABMT. 24 groups of conventional salvage chemotherapy (CSC) material of HD, which were published in 82-94, was analyzed in this article and dose-response relationship couldn't be found in it. But the outcome of CSC is disappointed, with only 23% CR response to MOPP and ABVD have a strong indication for ABMT.